Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' DEFICIT

v2.4.1.9
CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' DEFICIT (USD $)
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Stockholders' Equity - TransBiotec Inc.
Noncontrolling Interest
Total
Biginning Balance, Amount at Dec. 31, 2012 $ 303us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember
$ 11,903,279us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AdditionalPaidInCapitalMember
$ (14,274,244)us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= IMLE_DeficitAccumulatedDuringTheDevelopmentStageMember
$ (2,370,662)us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= IMLE_StockholdersEquityTransBiotecIncMember
$ (25,629)us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_NoncontrollingInterestMember
$ (2,396,291)us-gaap_StockholdersEquity
Beginning Balance, Shares at Dec. 31, 2012 30,315,554us-gaap_SharesIssued
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember
         
Stock issued for cash, Amount                  
Stock issued for services, Shares 833,333IMLE_StockIssuedForServicesShares
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember
         
Stock issued for services, Amount 9IMLE_StockIssuedForServicesAmount
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember
77,424IMLE_StockIssuedForServicesAmount
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AdditionalPaidInCapitalMember
   77,433IMLE_StockIssuedForServicesAmount
/ us-gaap_StatementEquityComponentsAxis
= IMLE_StockholdersEquityTransBiotecIncMember
   77,433IMLE_StockIssuedForServicesAmount
Stock conversion of note payable , Shares 2,997,825IMLE_StockConversionOfNotePayableShares
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember
         
Stock conversion of note payable, Amount 30IMLE_StockConversionOfNotePayableAmount
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember
48,970IMLE_StockConversionOfNotePayableAmount
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AdditionalPaidInCapitalMember
   49,000IMLE_StockConversionOfNotePayableAmount
/ us-gaap_StatementEquityComponentsAxis
= IMLE_StockholdersEquityTransBiotecIncMember
   49,000IMLE_StockConversionOfNotePayableAmount
Paid in capital - beneficial conversion feature   76,951IMLE_PaidInCapitalBeneficialConversionFeature
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AdditionalPaidInCapitalMember
   76,951IMLE_PaidInCapitalBeneficialConversionFeature
/ us-gaap_StatementEquityComponentsAxis
= IMLE_StockholdersEquityTransBiotecIncMember
   76,951IMLE_PaidInCapitalBeneficialConversionFeature
Paid in capital - stock option expense   145,997IMLE_PaidInCapitalStockOptionExpense
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AdditionalPaidInCapitalMember
   145,997IMLE_PaidInCapitalStockOptionExpense
/ us-gaap_StatementEquityComponentsAxis
= IMLE_StockholdersEquityTransBiotecIncMember
   145,997IMLE_PaidInCapitalStockOptionExpense
Paid in capital - Equity obligation settlement at fair value   163,018IMLE_PaidInCapitalEquityObligationSettlementAtFairValue
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AdditionalPaidInCapitalMember
   163,018IMLE_PaidInCapitalEquityObligationSettlementAtFairValue
/ us-gaap_StatementEquityComponentsAxis
= IMLE_StockholdersEquityTransBiotecIncMember
   163,018IMLE_PaidInCapitalEquityObligationSettlementAtFairValue
Share exchange - noncontrolling interest             (4,791)IMLE_ShareExchangeNoncontrollingInterest
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_NoncontrollingInterestMember
(4,791)IMLE_ShareExchangeNoncontrollingInterest
Net Loss      (758,416)IMLE_NetLoss
/ us-gaap_StatementEquityComponentsAxis
= IMLE_DeficitAccumulatedDuringTheDevelopmentStageMember
(758,416)IMLE_NetLoss
/ us-gaap_StatementEquityComponentsAxis
= IMLE_StockholdersEquityTransBiotecIncMember
   (758,416)IMLE_NetLoss
Ending Balance, Amount at Dec. 31, 2013 342us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember
12,415,639us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AdditionalPaidInCapitalMember
(15,032,660)us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= IMLE_DeficitAccumulatedDuringTheDevelopmentStageMember
(2,616,679)us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= IMLE_StockholdersEquityTransBiotecIncMember
(30,420)us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_NoncontrollingInterestMember
(2,647,099)us-gaap_StockholdersEquity
Ending Balance, Shares at Dec. 31, 2013 34,146,712us-gaap_SharesIssued
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember
         
Stock issued for services, Shares 154,520IMLE_StockIssuedForServicesShares
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember
         
Stock issued for services, Amount 2IMLE_StockIssuedForServicesAmount
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember
3,057IMLE_StockIssuedForServicesAmount
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AdditionalPaidInCapitalMember
   3,059IMLE_StockIssuedForServicesAmount
/ us-gaap_StatementEquityComponentsAxis
= IMLE_StockholdersEquityTransBiotecIncMember
   3,059IMLE_StockIssuedForServicesAmount
Stock conversion of note payable , Shares 24,115,428IMLE_StockConversionOfNotePayableShares
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember
         
Stock conversion of note payable, Amount 241IMLE_StockConversionOfNotePayableAmount
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember
66,878IMLE_StockConversionOfNotePayableAmount
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AdditionalPaidInCapitalMember
   67,119IMLE_StockConversionOfNotePayableAmount
/ us-gaap_StatementEquityComponentsAxis
= IMLE_StockholdersEquityTransBiotecIncMember
   67,119IMLE_StockConversionOfNotePayableAmount
Paid in capital - beneficial conversion feature   15,000IMLE_PaidInCapitalBeneficialConversionFeature
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AdditionalPaidInCapitalMember
   15,000IMLE_PaidInCapitalBeneficialConversionFeature
/ us-gaap_StatementEquityComponentsAxis
= IMLE_StockholdersEquityTransBiotecIncMember
   15,000IMLE_PaidInCapitalBeneficialConversionFeature
Paid in capital - stock option expense   69,886IMLE_PaidInCapitalStockOptionExpense
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AdditionalPaidInCapitalMember
   69,886IMLE_PaidInCapitalStockOptionExpense
/ us-gaap_StatementEquityComponentsAxis
= IMLE_StockholdersEquityTransBiotecIncMember
   69,886IMLE_PaidInCapitalStockOptionExpense
Paid in capital - Equity obligation settlement at fair value   146,170IMLE_PaidInCapitalEquityObligationSettlementAtFairValue
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AdditionalPaidInCapitalMember
   146,170IMLE_PaidInCapitalEquityObligationSettlementAtFairValue
/ us-gaap_StatementEquityComponentsAxis
= IMLE_StockholdersEquityTransBiotecIncMember
   146,170IMLE_PaidInCapitalEquityObligationSettlementAtFairValue
Share exchange - noncontrolling interest         (4,367)IMLE_ShareExchangeNoncontrollingInterest
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_NoncontrollingInterestMember
(4,367)IMLE_ShareExchangeNoncontrollingInterest
Net Loss      (744,562)IMLE_NetLoss
/ us-gaap_StatementEquityComponentsAxis
= IMLE_DeficitAccumulatedDuringTheDevelopmentStageMember
(744,562)IMLE_NetLoss
/ us-gaap_StatementEquityComponentsAxis
= IMLE_StockholdersEquityTransBiotecIncMember
   (744,562)IMLE_NetLoss
Ending Balance, Amount at Dec. 31, 2014 $ 585us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember
$ 12,716,630us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_AdditionalPaidInCapitalMember
$ (15,777,222)us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= IMLE_DeficitAccumulatedDuringTheDevelopmentStageMember
$ (3,060,007)us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= IMLE_StockholdersEquityTransBiotecIncMember
$ (34,787)us-gaap_StockholdersEquity
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_NoncontrollingInterestMember
$ (3,094,794)us-gaap_StockholdersEquity
Ending Balance, Shares at Dec. 31, 2014 58,416,660us-gaap_SharesIssued
/ us-gaap_StatementEquityComponentsAxis
= us-gaap_CommonStockMember